CA2558899C - Fused ring azadecalin glucocorticoid receptor modulators - Google Patents

Fused ring azadecalin glucocorticoid receptor modulators Download PDF

Info

Publication number
CA2558899C
CA2558899C CA2558899A CA2558899A CA2558899C CA 2558899 C CA2558899 C CA 2558899C CA 2558899 A CA2558899 A CA 2558899A CA 2558899 A CA2558899 A CA 2558899A CA 2558899 C CA2558899 C CA 2558899C
Authority
CA
Canada
Prior art keywords
fluoro
phenyl
hexahydro
triaza
cyclopenta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2558899A
Other languages
English (en)
French (fr)
Other versions
CA2558899A1 (en
Inventor
Robin D. Clark
Nicholas C. Ray
Paul M. Blaney
Christopher A. Hurley
Karen Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of CA2558899A1 publication Critical patent/CA2558899A1/en
Application granted granted Critical
Publication of CA2558899C publication Critical patent/CA2558899C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CA2558899A 2004-03-09 2005-03-09 Fused ring azadecalin glucocorticoid receptor modulators Expired - Lifetime CA2558899C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55183604P 2004-03-09 2004-03-09
US60/551,836 2004-03-09
PCT/US2005/008049 WO2005087769A1 (en) 2004-03-09 2005-03-09 Fused ring azadecalin glucocorticoid receptor modulators

Publications (2)

Publication Number Publication Date
CA2558899A1 CA2558899A1 (en) 2005-09-22
CA2558899C true CA2558899C (en) 2013-02-05

Family

ID=34961932

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2558899A Expired - Lifetime CA2558899C (en) 2004-03-09 2005-03-09 Fused ring azadecalin glucocorticoid receptor modulators

Country Status (17)

Country Link
US (4) US7928237B2 (https=)
EP (1) EP1735308B1 (https=)
JP (1) JP4931794B2 (https=)
KR (1) KR101185281B1 (https=)
CN (1) CN101027301B (https=)
AT (1) ATE407934T1 (https=)
AU (1) AU2005222421B2 (https=)
CA (1) CA2558899C (https=)
CY (1) CY1108621T1 (https=)
DE (1) DE602005009687D1 (https=)
DK (1) DK1735308T3 (https=)
ES (1) ES2313317T3 (https=)
IL (1) IL177982A (https=)
NZ (1) NZ550362A (https=)
PT (1) PT1735308E (https=)
WO (1) WO2005087769A1 (https=)
ZA (1) ZA200608306B (https=)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005222421B2 (en) * 2004-03-09 2010-09-23 Corcept Therapeutics, Inc. Fused ring azadecalin glucocorticoid receptor modulators
TWI410422B (zh) * 2007-01-15 2013-10-01 Mitsubishi Tanabe Pharma Corp 縮合四氫喹啉衍生物及其醫藥用途
EP2532350A1 (en) 2007-10-17 2012-12-12 Laboratoire HRA Pharma Pharmaceutical combination of a glucocorticoid receptor antagonist and a cortisol synthesis inhibitor for treating cushing's syndrome
US9216221B2 (en) 2008-11-07 2015-12-22 University Of Sheffield Medicament and method of diagnosis for treating subclinical Cushing's syndrome
ES2531040T3 (es) * 2009-05-12 2015-03-10 Corcept Therapeutics Inc Formas sólidas y procedimiento de preparación
EP2493303A4 (en) * 2009-10-30 2013-06-26 Merck Sharp & Dohme 2- [1-PHENYL-5-HYDROXY-4A-SUBSTITUTED HEXAHYDROCYCLOPENTA [F] INDAZOL-5-YL] ETHYLPHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS
WO2011087946A1 (en) * 2010-01-15 2011-07-21 Rigel Pharmaceuticals, Inc. Screening assay employing dex and gdf8
KR20130106378A (ko) * 2010-08-27 2013-09-27 코어셉트 쎄라퓨틱스, 잉크. 피리딜-아민 융합된 아자데칼린 조절제
US8829024B2 (en) 2011-01-07 2014-09-09 Corcept Therapeutics, Inc. Combination steroid and glucocorticoid receptor antagonist therapy
US9006568B2 (en) * 2012-02-15 2015-04-14 Phillips 66 Company Synthesis of photovoltaic conjugated polymers
US20130225633A1 (en) * 2012-02-27 2013-08-29 Corcept Therapeutics, Inc. Phenyl heterocycloalkyl glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PT4119561T (pt) * 2012-05-25 2024-09-30 Corcept Therapeutics Inc Moduladores de recetores de glucocorticoides de azadecalina fundida com heteroaril-cetona
US9691986B2 (en) 2012-12-03 2017-06-27 Solarmer Energy, Inc. Furan and selenophene derivatized benzo [1,2-b:4,5-b′] dithiophene-thienothiophene based conjugated polymers for high-efficiency organic solar cells
FI3848027T3 (fi) * 2013-11-25 2023-05-04 Corcept Therapeutics Inc Oktahydrofuusioituja atsadekaliiniglukokortikoidireseptorin modulaattoreita
WO2015077537A1 (en) * 2013-11-25 2015-05-28 Corcept Therapeutics, Inc. Heteroaryl-ether fused azadecalin glucocorticoid receptor modulators
CN107530435A (zh) * 2015-03-02 2018-01-02 科赛普特治疗学股份有限公司 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤
WO2016160969A1 (en) 2015-03-30 2016-10-06 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
ES2865334T3 (es) 2015-08-13 2021-10-15 Corcept Therapeutics Inc Método de diagnóstico diferencial de síndrome de Cushing dependiente de ACTH
US10312448B2 (en) 2015-10-01 2019-06-04 Phillips 66 Company Process of manufacturing an electron transport material
US9905769B2 (en) 2015-10-01 2018-02-27 Phillips 66 Company Process of manufacturing an electron transport material
WO2017058406A1 (en) 2015-10-01 2017-04-06 Phillips 66 Company Formation of films for organic photovoltaics
US9911919B2 (en) 2015-10-01 2018-03-06 Phillips 66 Company Process of manufacturing an electron transport material
US10418555B2 (en) 2015-10-01 2019-09-17 Phillips 66 Company Formation of films for organic photovoltaics
CA3011728A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome
IL297201A (en) 2016-03-01 2022-12-01 Corcept Therapeutics Inc Use of glucocorticoid receptor modulators to increase the activity of checkpoint inhibitors
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
JP7564620B2 (ja) 2017-03-09 2024-10-09 コーセプト セラピューティクス， インコーポレイテッド カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用
CA3055076C (en) 2017-03-31 2022-02-22 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
AU2018289307B2 (en) 2017-06-20 2024-02-01 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
IL263184A (en) 2018-11-21 2020-05-31 Yarden Yosef Method of treating cancer and compositions for same
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
FI3897589T3 (fi) 2018-12-19 2026-01-13 Corcept Therapeutics Inc Farmaseuttisia formulaatioita, jotka sisältävät relakorilanttia, heteroaryyliketonifusoitua atsekaliiniyhdistettä
JP7789561B2 (ja) 2019-02-22 2025-12-22 コーセプト セラピューティクス， インコーポレイテッド レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity
WO2021076565A1 (en) 2019-10-16 2021-04-22 Corcept Therapeutics Incorporated Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist
PH12022551430A1 (en) 2019-12-11 2023-11-20 Corcept Therapeutics Inc Methods of treating antipsychotic-induced weight gain with miricorilant
US20230358768A1 (en) 2019-12-21 2023-11-09 Corcept Therapeutics Incorporated Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
BR112022015011A2 (pt) 2020-01-29 2022-09-20 Corcept Therapeutics Inc Método para tratar um sujeito que sofre de tumor de carcinoma adrenocortical e tendo excesso de cortisol, e, composição farmacêutica para tratar carcinoma adrenocortical
CA3166901A1 (en) * 2020-02-10 2021-08-19 Corcept Therapeutics Incorporated Methods of stimulating an anti-tumor response using a selective glucocorticoid receptor modulator
US11285145B2 (en) 2020-05-27 2022-03-29 Corcept Therapeutics Incorporated Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4
AU2021296163B2 (en) 2020-06-22 2024-07-04 Corcept Therapeutics Incorporated Quaternary indazole glucocorticoid receptor antagonists
WO2022081725A1 (en) * 2020-10-16 2022-04-21 The Scripps Research Institute Therapeutic uses of glucocorticoids with anabolic effects in skeletal muscle
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2022166810A1 (zh) * 2021-02-03 2022-08-11 江苏恒瑞医药股份有限公司 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
CN114907340A (zh) * 2021-02-09 2022-08-16 江苏恒瑞医药股份有限公司 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
IL313663A (en) 2021-12-21 2024-08-01 Corcept Therapeutics Inc Piperazine indazole glucocorticoid receptor antagonists
KR20240125035A (ko) 2021-12-21 2024-08-19 코어셉트 쎄라퓨틱스 인코포레이티드 이환 인다졸 글루코코르티코이드 수용체 길항제
AU2023301396A1 (en) * 2022-06-28 2024-12-12 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CN117510490A (zh) * 2022-08-03 2024-02-06 江苏恒瑞医药股份有限公司 一种稠合氮杂萘烷类衍生物的晶型及其制备方法
IL319657A (en) 2022-10-06 2025-05-01 Corcept Therapeutics Inc Glucocorticoid receptor modulator formulations
WO2024092195A1 (en) 2022-10-28 2024-05-02 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant
CN120787227A (zh) * 2023-02-24 2025-10-14 科赛普特治疗公司 制备杂芳基-酮稠合的氮杂萘烷糖皮质激素受体调节剂的中间体的方法
WO2025152964A1 (en) * 2024-01-15 2025-07-24 Insilico Medicine Ip Limited Novel compounds as glucocorticoid receptor modulators and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828669D0 (en) * 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
EP1512683B1 (en) * 1998-03-10 2011-08-31 Research Triangle Institute Novel opiate compounds, methods of making and methods of use
GB9911053D0 (en) * 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
CA2473886C (en) * 2002-01-22 2012-08-21 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
AU2005222421B2 (en) * 2004-03-09 2010-09-23 Corcept Therapeutics, Inc. Fused ring azadecalin glucocorticoid receptor modulators
ES2531040T3 (es) * 2009-05-12 2015-03-10 Corcept Therapeutics Inc Formas sólidas y procedimiento de preparación

Also Published As

Publication number Publication date
NZ550362A (en) 2010-06-25
KR20070029684A (ko) 2007-03-14
US20140179671A1 (en) 2014-06-26
ZA200608306B (en) 2009-02-25
US20110166110A1 (en) 2011-07-07
US7928237B2 (en) 2011-04-19
EP1735308A1 (en) 2006-12-27
CA2558899A1 (en) 2005-09-22
US20120225856A1 (en) 2012-09-06
HK1104813A1 (en) 2008-01-25
IL177982A (en) 2012-09-24
EP1735308B1 (en) 2008-09-10
ES2313317T3 (es) 2009-03-01
CN101027301A (zh) 2007-08-29
AU2005222421A1 (en) 2005-09-22
CN101027301B (zh) 2011-06-29
CY1108621T1 (el) 2014-04-09
KR101185281B1 (ko) 2012-09-21
DE602005009687D1 (de) 2008-10-23
PT1735308E (pt) 2008-12-02
JP2007528417A (ja) 2007-10-11
US8557839B2 (en) 2013-10-15
AU2005222421B2 (en) 2010-09-23
WO2005087769A1 (en) 2005-09-22
ATE407934T1 (de) 2008-09-15
IL177982A0 (en) 2006-12-31
JP4931794B2 (ja) 2012-05-16
US20070281928A1 (en) 2007-12-06
DK1735308T3 (da) 2009-01-19

Similar Documents

Publication Publication Date Title
CA2558899C (en) Fused ring azadecalin glucocorticoid receptor modulators
CA2572544C (en) Modified pyrimidine glucocorticoid receptor modulators
US8324203B2 (en) Azadecalin glucocorticoid receptor modulators
CA2806900A1 (en) Pyridyl-amine fused azadecalin modulators
WO2013130420A1 (en) Phenyl heterocycloalkyl glucocorticoid receptor modulators
HK1104813B (en) Fused ring azadecalin glucocorticoid receptor modulators
HK1097768B (en) Modified pyrimidine glucocorticoid receptor modulators

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250911

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106